Biocytogen, on May 26th announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Centre, a fully automated infrastructure designed to accelerate antibody validation and production.
Built on Biocytogen’s proprietary RenMice platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery.
RenSuper Workstation: AI-Powered One-Click Target-to-Lead Therapeutic Antibody Discovery
RenSuper Workstation introduces a new paradigm for one-click therapeutic antibody discovery, transforming antibody discovery from a project-based workflow into a searchable and programmable system. The platform enables rapid identification of high-quality therapeutic candidates with strong developability, functional relevance, and translational potential.
Proprietary Fully Human Antibody Library
The platform provides off-the-shelf access to fully human antibody sequences against more than 1,000 validated targets, complete with data packages to support more confident decision-making.
AI-Powered Candidate Selection
RenSuper’s AI models are trained on more than 100 million biologically validated antibody sequences, enabling efficient candidate identification against structurally and biologically challenging targets.
Using Biocytogen’s RenNano fully human HCAb platform as an example, the AI-powered screening workflow achieved an average positive hit rate of 46%, with peak hit rates reaching 98%. The workflow also enriched candidates with superior developability profiles and delivered an 82% success rate for high-purity (≥90%) Fc-format antibody expression.
Experimentally Validated Antibody Sequences
All AI-selected antibody sequences undergo experimental validation, including binding, affinity, and specificity characterisation, ensuring reproducibility, reliability, and downstream development readiness.
One-Click Search & Design
The platform enables one-click filtering and comparison of antibody candidates by target, epitope, and physicochemical properties. An integrated antibody design platform further supports rapid sequence assembly and flexible format design across multiple therapeutic modalities.
More related news:
Biocytogen Pharmaceuticals signs a License Agreement With Pheon Therapeutics
Biocytogen and LiberoThera reach landmark in development of Fully Human GPCR Antibody Drugs
